S
Stephen Gottschalk
Researcher at St. Jude Children's Research Hospital
Publications - 294
Citations - 14336
Stephen Gottschalk is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Immunotherapy & Chimeric antigen receptor. The author has an hindex of 54, co-authored 249 publications receiving 11088 citations. Previous affiliations of Stephen Gottschalk include Charité & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed,Vita S. Brawley,Meenakshi Hegde,Catherine Robertson,Alexia Ghazi,Claudia Gerken,Enli Liu,Olga Dakhova,Aidin Ashoori,Amanda Corder,Tara Gray,Meng Fen Wu,Hao Liu,John Hicks,Nino Rainusso,Gianpietro Dotti,Zhuyong Mei,Bambi Grilley,Adrian P. Gee,Cliona M. Rooney,Malcolm K. Brenner,Helen E. Heslop,Winfried S. Wels,Lisa L. Wang,Peter M. Anderson,Stephen Gottschalk +25 more
TL;DR: This first evaluation of the safety and efficacy of HER2-CAR T cells in patients with cancer shows the cells can persist for 6 weeks without evident toxicities, setting the stage for studies that combine Her2- CAR T cells with other immunomodulatory approaches to enhance their expansion and persistence.
Journal ArticleDOI
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial
Nabil Ahmed,Nabil Ahmed,Vita S. Brawley,Vita S. Brawley,Meenakshi Hegde,Meenakshi Hegde,Kevin Bielamowicz,Mamta Kalra,Daniel Landi,Daniel Landi,Catherine Robertson,Tara Gray,Oumar Diouf,Amanda Wakefield,Amanda Wakefield,Alexia Ghazi,Claudia Gerken,Claudia Gerken,Zhongzhen Yi,Zhongzhen Yi,Aidin Ashoori,Meng Fen Wu,Hao Liu,Cliona M. Rooney,Gianpietro Dotti,Adrian P. Gee,Adrian P. Gee,Jack Su,Yvonne Kew,David S. Baskin,Yi Jonathan Zhang,Pamela New,Bambi Grilley,Bambi Grilley,Milica Stojakovic,Milica Stojakovic,John Hicks,Suzanne Zein-Eldin Powell,Malcolm K. Brenner,Helen E. Heslop,Robert G. Grossman,Winfried S. Wels,Stephen Gottschalk +42 more
TL;DR: Investigation of whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblastoma activity found them to be well tolerated.
Journal ArticleDOI
Design and development of therapies using chimeric antigen receptor-expressing T cells
TL;DR: The value of adding additional engineering features to CAR‐T cells, irrespective of their target, to render them better suited to function in the tumor environment, and the safety of these heavily modified cells may be maintained are shown.
Journal ArticleDOI
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Meenakshi Hegde,Malini Mukherjee,Malini Mukherjee,Zakaria Grada,Antonella Pignata,Daniel Landi,Shoba A. Navai,Amanda Wakefield,Kristen Fousek,Kevin Bielamowicz,Kevin Chow,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Stephen Gottschalk,Winfried S. Wels,Matthew L. Baker,Gianpietro Dotti,Maksim Mamonkin,Malcolm K. Brenner,Jordan S. Orange,Jordan S. Orange,Nabil Ahmed +22 more
TL;DR: TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.
Journal ArticleDOI
Post-transplant lymphoproliferative disorders.
TL;DR: Progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients.